4//SEC Filing
Sumitomo Pharma Co., Ltd. 4
Accession 0000899243-23-016487
CIK 0001635088other
Filed
Jun 25, 8:00 PM ET
Accepted
Jun 26, 4:05 PM ET
Size
11.7 KB
Accession
0000899243-23-016487
Insider Transaction Report
Form 4
Dainippon Sumitomo Pharma Co Ltd
10% Owner
Transactions
- Sale
Common Shares
2023-06-22$8.60/sh−15,116,277$129,999,982→ 71,251,083 total(indirect: See footnote)
Sumitomo Chemical Co., Ltd.
10% Owner
Transactions
- Sale
Common Shares
2023-06-22$8.60/sh−15,116,277$129,999,982→ 71,251,083 total(indirect: See footnote)
Footnotes (2)
- [F1]The sale reported on this Form 4 was effected pursuant to a privately negotiated transaction between Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma") and four purchasers. In connection with the transaction, Sumitomo Pharma entered into a customary lock-up agreement with Roivant Sciences Ltd. ("Roivant") covering the common shares that continue to be beneficially owned by Sumitomo Pharma following the transaction, which lock-up agreement is effective through February 29, 2024.The buyers also entered into customary lock-up agreements with Roivant covering the common shares acquired in the transaction, which lock-up agreements are effective through February 29, 2024.
- [F2]Sumitomo Pharma directly owns 71,251,083 Common Shares. Sumitomo Pharma is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Pharma owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.
Issuer
Roivant Sciences Ltd.
CIK 0001635088
Entity typeother
IncorporatedJapan
Related Parties
1- filerCIK 0001446601
Filing Metadata
- Form type
- 4
- Filed
- Jun 25, 8:00 PM ET
- Accepted
- Jun 26, 4:05 PM ET
- Size
- 11.7 KB